California Resources Corporation Announces January Investor Conference Participation
16. Dezember 2024 09:00 ET
|
California Resources Corporation
California Resources Corporation Announces January 2025 Investor Conference Participation
Carbon TerraVault and Net Power Sign MOU to Develop Low Carbon, Reliable Power Solutions in California
09. Dezember 2024 09:00 ET
|
Carbon TerraVault, LLC
Carbon TerraVault and Net Power Sign MOU to Develop Low Carbon, Reliable Power Solutions in California
California Resources Reports Third Quarter 2024 Financial and Operating Results
05. November 2024 16:31 ET
|
California Resources Corporation
California Resources Corporation Reports Third Quarter 2024 Financial and Operating Results
Carbon TerraVault Provides Third Quarter 2024 Update
05. November 2024 16:30 ET
|
Carbon TerraVault, LLC
Carbon TerraVault Provides Third Quarter 2024 Update
Kern County Board of Supervisors Advance CRC’s Carbon TerraVault I Project
21. Oktober 2024 17:00 ET
|
California Resources Corporation
Kern County Board of Supervisors unanimously approve the conditional use permit for CRC's Carbon TerraVault I carbon capture and storage project.
Colorado School of Mines and Carbon TerraVault Awarded $8.9 Million in DOE Funding for CarbonSAFE Project
08. Oktober 2024 09:00 ET
|
California Resources Corporation
Colorado School of Mines and Carbon TerraVault Awarded $8.9 Million in DOE Funding for CarbonSAFE Project
California Resources Corporation Schedules Third Quarter 2024 Earnings Conference Call
07. Oktober 2024 16:30 ET
|
California Resources Corporation
California Resources Corporation Schedules Third Quarter 2024 Earnings Conference Call for Wednesday, November 6, 2024 at 1:00 PM ET
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
08. August 2024 16:05 ET
|
Cardiff Oncology, Inc.
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP...
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
01. August 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
08. April 2024 16:05 ET
|
Cardiff Oncology, Inc.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...